Peijia Medical Limited announced that the first patient of the research clinical trial for Peijia's HighLife trans-septal mitral valve replacement ("TSMVR") system (the "System") has been enrolled in China. The first implant was successfully completed by Professor Mao Chen and his team from West China Hospital, Sichuan University, China on December 22, 2021. The Company's external consultant, Dr. Nicolo Piazza, an interventional cardiologist at McGill University in Montreal, Canada, teleproctored the procedure over a remote video connection. This is the first implant completed in Asia for TSMVR system produced by any manufacturer. The System is based on the technology developed by and transferred from HighLife SAS and is manufactured by the Company in China. It employs a unique. "Valve-in-Ring" concept, which makes the System self-centering and self-aligning. The 2-component design respectful for mitral valve anatomy can be adapted to a large majority of patients. The design of the System can mitigate the risk of paravalvular leakage and effectively reduce catheter size.